Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target
Wedbush analyst Robert Driscoll reiterates Crescent Biopharma (NASDAQ:CBIO) with a Outperform and maintains $27 price target.
Read original at benzingaStocks · News reference
Crescent Biopharma Q2 EPS $(0.74) Beats $(0.79) Estimate
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 30, 2026, 12:14 PM
- Checked
- Jul 30, 2026, 12:13 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Crescent Biopharma reported Q2 2026 results with continued enrollment in its ASCEND Phase 1/2 trial for CR-001, a PD-1 x VEGF bispecific antibody. The company completed a $143.7 million public offering extending cash runway to H2 2028 and announced multiple clinical data readouts expected beginning Q1 2027. R&D expenses increased to $19.4 million due to expanded clinical activities, while the company maintains strategic partnerships with Kelun-Biotech for development in Greater China.
Read original at globenewswire-inc8-K filing — CRESCENT BIOPHARMA, INC. (CBIO)
Filed: 2026-07-30 AccNo: 0001628280-26-050805 Size: 321 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar